CTT Pharma (CTTH)

Executive Summary

CTT Pharma is a U.S.-based drug delivery company that leverages its patented micelle thin-film technology to create better, faster, and more convenient oral drug delivery options. The company is currently in the 'Approved' stage, indicating that its technology platform has received regulatory clearance, and is now focused on commercializing micelle-encapsulated products. Initial product candidates include vitamin and bioactive supplement strips, as well as nicotine oral strips, which aim to capture share in the growing oral thin-film market. With a low valuation of ~$3.8M and a seasoned management team, CTT presents a unique opportunity in the drug delivery space. The company’s ability to scale production and secure distribution partnerships will be key to unlocking value. Given the approved status and tangible product roadmap, CTT is positioned for near-term revenue generation.

Upcoming Catalysts (preview)

• Q3 2026Launch of nicotine oral strips70% success
• Q4 2026Expansion of vitamin supplement strip product line65% success
• TBDPartnership or licensing deal with a large pharmaceutical company40% success